MGCD265
Phase 1/2- Indications
- Solid tumors, Non-small cell lung cancer
Company intelligence / Profile preview
MethylGene Inc.
Montreal, Quebec, Canadapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
MethylGene developed small molecule therapeutics targeting cancer and infectious diseases. Its lead candidates included MGCD265 (multi-targeted kinase inhibitor for solid tumors), MGCD290 (fungal Hos2 inhibitor for candidiasis), mocetinostat/MGCD0103 (HDAC inhibitor for cancer), and EVP‑0334 for neurodegenerative disease. Several programs reached Phase I or II trials but were discontinued or licensed out as the company ceased independent operations.[1][5]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules[5][6]Enzyme inhibitorsKinase inhibitorsHDAC inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Otsuka Pharmaceutical Co. Ltd. – collaboration on ocular disease applications using proprietary kinase chemistry [5].Taiho Pharmaceutical Co. Ltd. – licensee of mocetinostat in certain Asian countries [5].EnVivo Pharmaceuticals – sponsored development of EVP‑0334 for neurodegeneration [5].
Beyond the preview
Go deeper on MethylGene Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MethylGene Inc..